Tonix Pharmaceuticals Holding Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNXP research report →
Companywww.tonixpharma.com
Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates.
- CEO
- Seth Lederman
- IPO
- 2012
- Employees
- 81
- HQ
- Chatham, NJ, US
Price Chart
Valuation
- Market Cap
- $231.14M
- P/E
- -1.35
- P/S
- 13.17
- P/B
- 0.88
- EV/EBITDA
- -0.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 52.62%
- Op Margin
- -861.16%
- Net Margin
- -839.52%
- ROE
- -67.65%
- ROIC
- -66.19%
Growth & Income
- Revenue
- $13.11M · 29.85%
- Net Income
- $-124,021,000 · 4.63%
- EPS
- $-14.57 · 91.75%
- Op Income
- $-125,703,000
- FCF YoY
- -69.08%
Performance & Tape
- 52W High
- $69.97
- 52W Low
- $11.60
- 50D MA
- $13.74
- 200D MA
- $19.96
- Beta
- 1.69
- Avg Volume
- 424.40K
Get TickerSpark's AI analysis on TNXP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Stillwell Richard Newcomb | other | 22,700 |
| May 12, 26 | OLUKOTUN ADEOYE Y | other | 22,700 |
| May 12, 26 | Bell Margaret Smith | other | 22,700 |
| May 12, 26 | Hunter James Randolph Jr | other | 22,700 |
| May 12, 26 | Treco James | other | 22,700 |
| May 12, 26 | GRANGE DAVID L | other | 22,700 |
| May 12, 26 | BAGGER RICHARD H | other | 22,700 |
| May 12, 26 | Taylor Carolyn E. | other | 22,700 |
| Mar 31, 26 | LEDERMAN SETH | buy | 5,000 |
| Mar 18, 26 | LEDERMAN SETH | buy | 15,000 |
Our TNXP Coverage
We haven't published any research on TNXP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TNXP Report →